Skip to content
thestock.space

NATCO Pharma (NATCOPHARM) had a P/E of 12.7× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 34% below their 52-week high. Sales and net profit grew 14% and 26% a year over 3 years, with ROCE of 16% and ROE of 17%. It carries very little debt, and its dividend yield is 0.7%. It is a small-cap company with a market cap of ₹15,831 Cr, ranked 29th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 2.8% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹799.00
Day high
₹821.15
Day low
₹795.05
Prev. close
₹796.60
Volume
7.1 L

Health check

2 good · 2 fair · 2 to check
  • ReturnsBehind

    −2.8% over a year, better than 1 of 7 peers.

  • Price tagCheaper

    P/E 12.7 vs industry 28.7.

  • GrowthStrong

    Sales +14.5%, profit +25.6% a year over 3 years.

  • ProfitabilityAverage

    ROCE 16.1% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.08× equity, interest covered 58.8×, Piotroski 5 of 9.

  • Red flags4 to check

    Quarterly profit down 57.0% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹15,831 Cr, #29 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹3,485 Cr · profit ₹1,144 Cr
Market cap
₹15,831 Cr
Small cap
P/E
12.7
Industry 28.7
Price to book
1.57
Peers 4.99
Dividend yield
0.74%
ROE
16.9%
Peers 14.7%
ROCE
16.1%
Peers 17.9%
Debt to equity
0.08
Debt ₹714 Cr
EPS (TTM)
₹63.37
Face value ₹2
OPM (TTM)
30.2%
Net margin 32.8%
Sales growth
−44.7%
Latest quarter vs a year ago
Profit growth
−57.0%
Latest quarter vs a year ago
Price to sales
4.54
EV/EBITDA 12.2

Strengths and risks

Strengths

  • Practically debt-free.
  • Net margin of 32.8%.
  • P/E of 12.7 against an industry P/E of 28.7.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Quarterly profit down 57.0% on a year ago.
  • Quarterly sales down 44.7% on a year ago.
  • 34% below its 52-week high.
  • Promoter stake down from 49.5% to 46.2%.

Derived automatically from reported figures. Not a recommendation.

About NATCO Pharma

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and…

Headquarters
Hyderabad
Employees
4,433
Sector
Healthcare
ISIN
INE987B01026
Website
natcopharma.co.in

Price range

52 weeks

₹773.60₹1,226.80

Today

₹795.05₹821.15
Avg volume (3M)
4.8 L
1-year return
minus 2.8%
From 52-week high
minus 34.2%

Analyst consensus

9 analysts
No consensusMean target ₹1,004.44 plus 24.5%

Target range, with today’s price

Low ₹712.00High ₹1,180.00

Next results expected around 13 Nov 2026

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
NATCOPHARMNATCO Pharma807.00plus 1.31%15,83112.71.5716.1%16.9%30.2%14.5%25.6%0.74%minus 2.8%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
1,3291,363647739735
758784489612549
571579159128187
43.0%42.5%24.5%17.3%25.4%
61.710058.177.859.2
3.213.19.510.913
57.652.446.250.447.1
572614161144186
16.0%15.6%12.8%−61.9%34.2%
481518152268207
26.8428.948.4614.9611.53

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+14.5%
Profit CAGR 3Y
+25.6%
EPS CAGR 3Y
+26.4%
ROE
16.9%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2,6973,9794,4124,045
–+47.5%+10.9%minus 8.3%
1,7432,2152,1952,582
9541,7642,2161,463
35.4%44.3%50.2%36.2%
81.8116241287
9.5121725.8
164187235207
−0.5−7.586−26.2
8621,6742,2911,491
17.0%17.0%17.8%8.0%
7151,3881,8851,419
–+94.1%+35.8%minus 24.8%
39.1877.34105.2679.20

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
36.535.835.835.8
4,8375,8177,5719,185
176371279714
6086827441,139
5,6576,9068,63111,074
2,3302,5042,7062,909
91.2206274363
87.395.9154273
1,1251,7762,8082,788
2,0242,3242,6894,740
5,6576,9068,63111,074

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
8491,2121,6971,768
−477−1,033−1,415−2,082
−363−247−211298
9−6871.6−15.9
−206−359−512−391
6448531,1851,377
−100−171−108−90.2

Shareholding pattern

Source: NSE filings
46.2%
promoters
  • Promoters46.22%
  • Public53.78%
  • As of 23 Oct 2026
QuarterSplitPromotersPublicPromoter change
23 Oct 202646.22%53.78%minus 3.17
30 Sep 202649.39%50.61%minus 0.03
30 Jun 202649.42%50.58%0.00
31 Mar 202649.42%50.58%minus 0.06
31 Dec 202549.48%50.52%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you